Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric ...

In a small clinical trial in Canada, a medicine commonly found in European cough syrups has shown early signs it might do ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

Researchers at the Lawson Health Research Institute, part of St. Joseph’s Health Care London, are studying Ambroxol, a cough ...

Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

Ambroxol is at the center of another Parkinson's study, which isn't linked to dementia outcomes but a rare genetic condition known as Gaucher disease, and the Phase III two-year trial results are ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...